Linked Life Data

10665763

Source:http://linkedlifedata.com/resource/pubmed/id/10665763

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2000-2-15
pubmed:abstractText
The monoclonal antibody PC10 is used for immunohistochemical staining of the proliferating cell nuclear antigen (PCNA). The percentage of PC10-positive cancer cells is defined as the PC10 index. We evaluated the relationship between the PC10 index in pretreatment endoscopic biopsies and the prognoses of 47 patients with Stage II-III oesophageal squamous cell carcinoma treated with radiotherapy. The patients with a PC10 index > 40% had significantly poorer prognoses than the other patients (p = 0.0007). Proportional hazards model analysis indicated that only the PC10 index was a prognostic factor (p = 0.0009). The patient group of complete responders showed significantly lower PC10 indices compared to patients with a partial response or no change (p = 0.049). The PC10 index can be a good predictive indicator of the prognosis in patients with Stage II-III oesophageal cancer treated with radiotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0284-186X
pubmed:author
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1057-62
pubmed:dateRevised
2009-5-12
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Prognostic significance of the PC10 index for patients with stage II and III oesophageal cancer treated with radiotherapy.
pubmed:affiliation
Department of Radiology, Hitachi General Hospital, Hitachi-shi, Ibaraki, Japan. sugahara@cm.nichibyo.hitachi.co.jp
pubmed:publicationType
Journal Article